Wall Street analysts expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post sales of $3.96 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Crispr Therapeutics’ earnings, with estimates ranging from $250,000.00 to $14.80 million. Crispr Therapeutics reported sales of $211.93 million in the same quarter last year, which indicates a negative year over year growth rate of 98.1%. The business is expected to report its next earnings results on Monday, October 26th.
On average, analysts expect that Crispr Therapeutics will report full-year sales of $7.19 million for the current year, with estimates ranging from $200,000.00 to $29.90 million. For the next financial year, analysts anticipate that the business will report sales of $38.67 million, with estimates ranging from $3.50 million to $90.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, July 27th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.35). Crispr Therapeutics had a return on equity of 2.35% and a net margin of 6.77%. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. During the same period in the previous year, the firm earned ($1.01) earnings per share. Crispr Therapeutics’s revenue was down 86.2% on a year-over-year basis.
Several research firms have issued reports on CRSP. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. SunTrust Banks assumed coverage on Crispr Therapeutics in a report on Tuesday, July 14th. They issued a “buy” rating and a $140.00 target price on the stock. Needham & Company LLC upped their price objective on shares of Crispr Therapeutics from $84.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Roth Capital boosted their price target on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the company a “buy” rating in a report on Friday, June 19th. Finally, William Blair restated a “buy” rating on shares of Crispr Therapeutics in a research report on Tuesday, July 28th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $90.93.
In related news, COO Lawrence Otto Klein sold 65,088 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $75.93, for a total value of $4,942,131.84. Following the transaction, the chief operating officer now owns 58,666 shares in the company, valued at $4,454,509.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael John Tomsicek sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $92.26, for a total transaction of $1,107,120.00. Following the completion of the sale, the chief financial officer now directly owns 12,410 shares of the company’s stock, valued at $1,144,946.60. The disclosure for this sale can be found here. In the last three months, insiders have sold 284,246 shares of company stock valued at $23,578,888. Insiders own 21.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of CRSP. Capital Advisors Inc. OK grew its stake in shares of Crispr Therapeutics by 2.2% in the second quarter. Capital Advisors Inc. OK now owns 136,497 shares of the company’s stock worth $12,686,000 after acquiring an additional 2,918 shares during the last quarter. Handelsbanken Fonder AB acquired a new stake in Crispr Therapeutics in the 2nd quarter worth $441,000. Stephens Inc. AR bought a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $643,000. Private Advisor Group LLC raised its position in shares of Crispr Therapeutics by 7.0% during the second quarter. Private Advisor Group LLC now owns 5,207 shares of the company’s stock valued at $383,000 after buying an additional 340 shares during the last quarter. Finally, Orbimed Advisors LLC raised its position in shares of Crispr Therapeutics by 26.5% during the second quarter. Orbimed Advisors LLC now owns 697,524 shares of the company’s stock valued at $51,261,000 after buying an additional 146,324 shares during the last quarter. 55.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CRSP traded down $3.67 during mid-day trading on Thursday, hitting $82.02. The company’s stock had a trading volume of 1,570,215 shares, compared to its average volume of 874,703. Crispr Therapeutics has a fifty-two week low of $32.30 and a fifty-two week high of $105.12. The stock has a market capitalization of $5.76 billion, a price-to-earnings ratio of 178.30 and a beta of 2.29. The firm has a 50-day moving average price of $90.72 and a 200 day moving average price of $65.65.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.